Phaseline

Companies › ReAlta Life Sciences

ReAlta Life Sciences: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 2; Immunology, Other, Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RLS-0071
Novel peptide
–Phase 2Acute Exacerbation of Chronic Obstructive Pulmonary Disease; Steroid Refractory GVHD; Hypoxic-Ischemic EncephalopathyDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06175065RLS-0071Phase 2Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseRespiratoryJun 2025
NCT06343792RLS-0071Phase 2Steroid Refractory GVHDImmunologyDec 2026
NCT05778188RLS-0071Phase 2Hypoxic-Ischemic EncephalopathyOtherDec 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Prana Therapies Enveda Therapeutics Clarent Biopharma Optinose US Kymera Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.